| Literature DB >> 35874845 |
Shweta Patel1, K Pushpalatha1, Bharti Singh1, Ragini Shrisvastava2, Gyanendra Singh3, Deepti Dabar3.
Abstract
Menstrual disturbances are common among adolescents with a prevalence rate of 11.3-26.7%. The most frequent menstrual irregularities are oligomenorrhea, menorrhagia, polymenorrhoea, and hypomenorrhea. PCOS (polycystic ovarian syndrome) is now recognized as the most prevalent endocrine disorder among the women of reproductive age. The current study was planned to evaluate socio-demographic factors, endocrine profiles, and ovarian morphology among adolescent girls with menstrual irregularities and compare these parameters in different phenotypes of adolescent PCOS cases. It is a hospital-based cross-sectional study among 248 adolescent girls (10-19 years) with menstrual irregularities. After obtaining informed consent, history and clinical examination findings were recorded on preform proforma. All girls were assessed on day 2/3 of the menstrual cycle for hormonal profile (serum TSH, FSH, LH, prolactin, and serum testosterone) and ovarian morphology (by transabdominal ultrasonography). All participating girls were divided into three groups (groups 1, 2, and 3) corresponding to phenotypes A, B, & D as per the Rotterdam criteria. In the study, oligomenorrhea was the most common menstrual disorder (70.97%). Biochemical hyperandrogenism and thyroid dysfunction were reported in 14.91% and 8.46% of girls, respectively. Our study noted that phenotype D ,i.e., group 3 (MI + PCOM-HA; 49.43%) was the most common phenotype in the study. In a comparative analysis of different groups, significant differences (p < 0.05) in hormonal and metabolic parameters showed highest in group 2, which represents phenotype B of PCOS (hyperandrogenic anovulation). This analysis revealed that adolescent hyperandrogenism (phenotypes A and B) is associated with a more deranged hormonal and metabolic profile than nonandrogenic PCOS (phenotype D). To prevent long-term sequelae, lifestyle changes, early treatment, and close follow-up are recommended in this subset of girls.Entities:
Mesh:
Year: 2022 PMID: 35874845 PMCID: PMC9307389 DOI: 10.1155/2022/3047526
Source DB: PubMed Journal: ScientificWorldJournal ISSN: 1537-744X
Figure 1Diagnostic criteria for polycystic ovary syndrome [8].
Figure 2Phenotypes of polycystic ovary syndrome as per the Rotterdam criteria [11].
Demographic and clinical characteristics of study population.
| S.N. | Demographic variables |
| ||
|---|---|---|---|---|
| 1 | Mean agee | 17.08 ± 1.91 | ||
|
| ||||
| 2 | Age at menarcheea | 11.97 ± 1.025 | ||
|
| ||||
| 3 | Socio economic status | Upper | 9/248 | 03.62 |
| Upper-middle | 80/248 | 32.25 | ||
| Lower-middle | 99/248 | 39.91 | ||
| Upper-lower | 43/248 | 17.33 | ||
| Lower | 17/248 | 06.85 | ||
|
| ||||
| 4 | Family history of menstrual disorder | Present | 86/248 | 34.67 |
| Absent | 108/248 | 43.54 | ||
| Not sure | 54/248 | 21.77 | ||
|
| ||||
| 5 | Menstrual complaint | Oligomenorrhoea | 176/248 | 70.96 |
| Polymenorrhea | 22/248 | 08.87 | ||
| Menorrhagia/menometrorrhagia | 42/248 | 16.93 | ||
| Hypomenorrhoea | 08/248 | 03.22 | ||
adata are shown as mean ± SD; bdata are shown as n(%).
Figure 3Study flow chart.
Endocrinal profile in adolescents with menstrual irregularities.
| S. N. | Menstrual irregularities | Total no of cases ( | Thyroid dysfunction | Hyperprolactinemia | Biochemical hyperandrogenism | |||
|---|---|---|---|---|---|---|---|---|
| No ( | % (8.46%) | No ( | % (1.20%) | No ( | % (14.91%) | |||
| 1. | Oligomenorrhoea | 176 | 13 | 07.38 | 02 | 1.12 | 33 | 18.75 |
| 2. | Polymenorrhoea | 22 | 02 | 09.09 | 0 | 0.0 | 01 | 04.54 |
| 3. | Menorrhagia | 42 | 05 | 11.90 | 0 | 0.0 | 02 | 04.76 |
| 4. | Hypomenorrhoea | 08 | 01 | 12.50 | 01 | 12.50 | 01 | 12.50 |
Data are shown as n (%)
Clinical characteristics of different phenotypic groups of adolescents with menstrual irregularities.
| Variables | Group- 1 | Group-2 | Group-3 |
| |
|---|---|---|---|---|---|
| Family history of PCOS | |||||
| Present | 26 (65.0) | 15 (60.0) | 20 (22.98) | 0.05 | |
| Absent | 14 (35.0) | 10 (40.0) | 67 (77.07) | ||
|
| |||||
| History of weight gain | |||||
| Present | 20 (50.0) | 14 (56.0) | 16 (18.39) | 0.001 | |
| Absent | 20 (50.0) | 11 (34.0) | 71 (81.60) | ||
|
| |||||
| Hyperandrogenism | |||||
| Acne | Present | 20 (50.0) | 11 (44.0) | NA | |
| Absent | 20 (50.0) | 14 (66.0) | |||
| Hirsutism | Present | 13 (32.5) | 12 (48.0) | ||
| Absent | 27 (67.5) | 13 (52.0) | |||
| Biochemical hyperandrogenemia | Present | 16 (40.0) | 09 (36.0) | ||
| Absent | 24 (60.0) | 16 (64.0) | |||
|
| |||||
| BMI ≥ 23 | |||||
| Present | 27 (67.5) | 15 (60.0) | 17 (19.54) | ||
| Absent | 13 (32.5) | 10 (40.0) | 70 (80.45) | ||
|
| |||||
| Ovarian morphology | |||||
| Bilateral PCOM | 37 (92.5) | NA | 67 (77.01) | ||
| Right PCOM | 03 (07.5) | 14 (16.09) | |||
| Left PCOM | 0 (0.0) | 6 (06.89) | |||
Group 1: MI + HA(C/B) + PCOM, group 2: MI + HA(C/B)-PCOM, and group:3 MI + PCOM -HA(C/B) data are shown as n (%); MI: menstrual irregularities; HA: hyperandrogenemia; C: clinical (moderate to severe acne/hirsutism mFG score ≥8,); B: biochemical (S. testosterone ≥82 ng/dl); PCOM: polycystic ovarian morphology, BMI: body mass index. p values were evaluated by using the chi-square test.
Comparative analysis of endocrinal metabolic and hormonal parameters in different phenotypes of adolescent PCOS.
| Variables | Group 1 mean ± SD (95% CI) | Group 2 mean ± SD (95% CI) | Group 3 mean ± SD (95% CI) | p-value | Bonferroni post hoc test ( |
|---|---|---|---|---|---|
| S.FSH mIU/ml | 6.89 ± 1.85 (6.24–7.54) | 7.09 ± 1.7 (5.96–8.23) | 6.85 ± 2.72 (6.21`-7.49) | 0.94 | |
| S. LH mIU/ml | 11.78 ± 2.56 (10.88–12.67) | 13.10 ± 3.22 (11.05–15.15) | 9.82 ± 3.25 (9.05–10.58 | <0.001 | 1 vs 3, 2vs 3 |
| BMI | 23.91 ± 3.53 (22.78–25.04) | 23.44 ± 3.64 (21.93–24.94) | 20.53 ± 2.98 (19.90–21.17) | <0.001 | 1 vs 3, 2vs 3 |
| S. fasting glucose mg/dl | 89.72 ± 11.78 (85.73–93.70) | 85.59 ± 11.31 (79.05–92.12) | 80.05 ± 11.12 (77.52–82.57) | <0.001 | 1 vs 3 |
| S. fasting insulin ( | 21.42 ± 4.26 (19.73–23.11) | 23.58 ± 3.16 (21.45–25.71) | 20.20 ± 3.93 (19.23–21.17) | 0.026 | 2 vs 3 |
| S. testosterone | 77.24 ± 28.84 (67.18–87.30) | 91.24 ± 30.75 (71.70–110.78) | 47.22 ± 14.49 (43.81–50.62) | <0.001 | 1 vs3, 2 vs 3 |
Group 1: MI + HA(C/B) + PCOM, group 2: MI + HA(C/B)-PCOM, and group:3 MI + PCOM -HA(C/B) data are shown as mean ± SD; O: oligomenorrhoea; HA: hyperandrogenemia; C: clinical (moderate to severe acne/hirsutism mFG score ≥ 8; PCOM: polycystic ovarian morphology; S. FSH: serum follicular stimulating hormone; S. LH: Serum leutinizing hormone; BMI: body mass index. p-values were evaluated by one-way ANOVA; significance difference between any two group (p < 0.05), as demonstrated by the Bonferroni post hoc test.